

DAFTAR PUSTAKA

1. Paliogiannis, P., Fois, A. G., Sotgia, S., Mangoni, A. A., Zinellu, E., Pirina, P., ... & Zinellu, A. (2018). Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. *European Respiratory Review*, 27(147).
2. Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: risk factors, prevalence, and future trends. *The Lancet*, 370(9589), 765-773.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report)
4. Perhimpunan Dokter Paru Indonesia (PDPI). PPOK (Penyakit Paru Obstruktif Kronik), Diagnosis dan Penatalaksanaan. Jakarta: UI Press, 2016.
5. Yudhawati, R., & Prasetyo, Y. D. (2018). Imunopatogenesis penyakit paru obstruktif kronik. *Jurnal Respirasi*, 4(1), 19-25.
6. MacNee, W. (2005). Pathogenesis of chronic obstructive pulmonary disease. *Proceedings of the American thoracic society*, 2(4), 258-266.
7. Wouters, E. F. (2005). Local and systemic inflammation in chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, 2(1), 26-33.
8. Yousef, A. M., & Alkhiary, W. (2017). Role of neutrophil to lymphocyte ratio in prediction of acute exacerbation of chronic obstructive pulmonary disease. *Egyptian Journal of Chest Diseases and Tuberculosis*, 66(1), 43-48.
9. Zinellu, A., Zinellu, E., Mangoni, A. A., Pau, M. C., Carru, C., Pirina, P., & Fois, A. G. (2022). Clinical significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute exacerbations of COPD: present and future. *European Respiratory Review*, 31(166).
10. Pascual-Gonzalez, Y., Lopez-Sanchez, M., Dorca, J., & Santos, S. (2018). Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review. *International journal of chronic obstructive pulmonary disease*, 3651-3662.
11. Tudorache, E., Fildan, A. P., Fira-Mladinescu, O., Marc, M., & Tudorache, C. (2020). Risk factors of chronic obstructive pulmonary disease exacerbations. *The clinical respiratory journal*, 14(3), 183-197



12. Li, J., Sun, S., Tang, R., Qiu, H., Huang, Q., Mason, T. G., & Tian, L. (2016). Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis. *International journal of chronic obstructive pulmonary disease*, 11, 3079–3091
13. Santurtún, A., Rasilla, D. F., Riancho-Zarrabeitia, L., & Zarrabeitia, M. T. (2017). Relationship between chronic obstructive pulmonary disease and air pollutants depending on the origin and trajectory of air masses in the north of Spain. *Archivos de Bronconeumología (English Edition)*, 53(11), 616-621
14. Miravittles, M., & Anzueto, A. (2017). Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics?. *International journal of molecular sciences*, 18(7), 1344
15. Soriano, J. B. (2017). An epidemiological overview of chronic obstructive pulmonary disease: what can real-life data tell us about disease management?. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 14(sup1), S3-S7
16. Lawlor, D. A., Ebrahim, S., & Smith, G. D. (2005). Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. *Thorax*, 60(10), 851-858
17. Stoller, J. K., & Aboussouan, L. S. (2005). α 1-antitrypsin deficiency. *The Lancet*, 365(9478), 2225-2236
18. Joshua, J. S., & Thomas, P. S. (2015). COPD: Immunopathogenesis and Immunological Markers. *Advanced in Research*, 3(2), 221-235
19. Kaminsky DA. The Netter Collection of Medical Illustration 2nd Edition Volume 3: Respiratory System. Vol. 3, Elsevier Saunders. 2011. Page 345
20. Sethi, S., Mahler, D. A., Marcus, P., Owen, C. A., Yawn, B., & Rennard, S. (2012). Inflammation in COPD: implications for management. *The American journal of medicine*, 125(12), 1162-1170
21. O'donnell, R., Breen, D., Wilson, S., & Djukanovic, R. (2006). Inflammatory cells in the airways in COPD. *Thorax*, 61(5), 448-454
22. Bathoorn, E., Kerstjens, H., Postma, D., Timens, W., & MacNee, W. (2008). Airways inflammation and treatment during acute exacerbations of COPD. *International journal of chronic obstructive pulmonary Disease*, 3(2), 217-229
- zicha, J. A., & Seemungal, T. A. (2007). COPD exacerbations: defining cause and prevention. *The lancet*, 370(9589), 786-796



24. Rosales, C. (2018). Neutrophil: a cell with many roles in inflammation or several cell types?. *Frontiers in physiology*, 9, 113
25. Barbu, C., Iordache, M., & Man, M. G. (2011). Inflammation in COPD: pathogenesis, local and systemic effects. *Rom J Morphol Embryol*, 52(1), 21-27.
26. Vlahos, R., & Bozinovski, S. (2014). Role of alveolar macrophages in chronic obstructive pulmonary disease. *Frontiers in immunology*, 5, 435.
27. Kitaguchi, Y., Fujimoto, K., Kubo, K., & Honda, T. (2006). Characteristics of COPD phenotypes classified according to the findings of HRCT. *Respiratory medicine*, 100(10), 1742-1752.
28. Brightling, C. E., Monteiro, W., Ward, R., Parker, D., Morgan, M. D., Wardlaw, A. J., & Pavord, I. D. (2000). Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. *The Lancet*, 356(9240), 1480-1485.
29. Hewson, C. A., Jardine, A., Edwards, M. R., Laza-Stanca, V., & Johnston, S. L. (2005). Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. *Journal of virology*, 79(19), 12273-12279.
30. Ritter, M., Mennerich, D., Weith, A., & Seither, P. (2005). Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly (I: C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. *Journal of inflammation*, 2, 1-15.
31. Jeffery PK, Pathology of asthma compared with chronic obstructive pulmonary disease. In: Adkinson F, Busse WW, Bochner BS, Holgate ST, Simons FER, Lemanske RF (eds), *Middleton's allergy: principles and practice*, 7th edition, Mosby, 2009, 921–936
32. Barnes, P. J. (2019). Inflammatory endotypes in COPD. *Allergy*, 74(7), 1249-1256.
33. Hao, S., Yuan, Y., Ye, W., & Fang, X. (2023). Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality in Critically Ill Patients with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, 29, e938554-1.



World Health Organization. The Global Health Observatory, Global Health Estimates: Life expectancy and leading causes of death and disability.

Available from: <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates>

35. Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. *PLoS medicine*, 3(11), e442.
36. Barnes, P. J. (2016). Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, 138(1), 16-27.
37. Brightling, C., & Greening, N. (2019). Airway inflammation in COPD: progress to precision medicine. *European Respiratory Journal*, 54(2).
38. Fermont, J. M., Masconi, K. L., Jensen, M. T., Ferrari, R., Di Lorenzo, V. A., Marott, J. M., ... & Wood, A. M. (2019). Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. *Thorax*, 74(5), 439-446.
39. Song, W., Wang, Y., Tian, F., Ge, L., Shang, X., Zeng, Q., ... & Ma, X. (2021). Clinical significance of procalcitonin, C-reactive protein, and interleukin-6 in helping guide the antibiotic use for patients with acute exacerbations of chronic obstructive pulmonary disease. *Disease Markers*, 2021.
40. Thomsen, M., Ingebrigtsen, T. S., Marott, J. L., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2013). Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. *Jama*, 309(22), 2353-2361.
41. Hoult, G., Gillespie, D., Wilkinson, T. M., Thomas, M., & Francis, N. A. (2022). Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis. *BMC Pulmonary Medicine*, 22(1), 194.
42. Ni, W., Bao, J., Yang, D., Xi, W., Wang, K., Xu, Y., ... & Gao, Z. (2019). Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. *Infectious Diseases*, 51(9), 639-650.
43. Sakurai, K., Chubachi, S., Irie, H., Tsutsumi, A., Kameyama, N., Kamatani, T., ... & Betsuyaku, T. (2018). Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. *BMC pulmonary medicine*, 18(1), 1-11.
44. Günay, E., Sarınc Ulaşlı, S., Akar, O., Ahsen, A., Günay, S., Koyuncu, T., & ... M. (2014). Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. *Inflammation*, 37, 374-380.
45. ... , C. H., Wang, Z. M., & Chen, S. Y. (2018). Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary



syndrome: A systematic review and meta-analysis. *Clinical biochemistry*, 52, 131-136.

46. Li, W., Hou, M., Ding, Z., Liu, X., Shao, Y., & Li, X. (2021). Prognostic value of neutrophil-to-lymphocyte ratio in stroke: a systematic review and meta-analysis. *Frontiers in Neurology*, 12, 686983.
47. Fu, W., Fu, H., Ye, W., Han, Y., Liu, X., Zhu, S., ... & Wang, Q. (2021). Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: a meta-analysis. *International immunopharmacology*, 101, 108235.
48. Huang, Z., Fu, Z., Huang, W., & Huang, K. (2020). Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. *The American journal of emergency medicine*, 38(3), 641-647.
49. Cupp, M. A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., & Berlanga-Taylor, A. J. (2020). Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. *BMC medicine*, 18, 1-16.
50. Li, X., Liu, C., Mao, Z., Xiao, M., Wang, L., Qi, S., & Zhou, F. (2020). Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. *Critical Care*, 24(1), 1-10.
51. Farah, R., Ibrahim, R., Nassar, M., Najib, D., Zivony, Y., & Eshel, E. (2017). The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD. *Panminerva medica*, 59(3), 203-209.
52. Teng, F., Ye, H., & Xue, T. (2018). Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease. *PLoS One*, 13(9), e0204377.
53. El-Gazzar, A. G., Kamel, M. H., Elbahnasy, O. K. M., & El-Naggar, M. E. S. (2020). Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. *Expert Review of Respiratory Medicine*, 14(1), 111-116.
54. Lu, F. Y., Chen, R., Li, N., Sun, X. W., Zhou, M., Li, Q. Y., & Guo, Y. (2021). Neutrophil-to-lymphocyte ratio predicts clinical outcome of severe acute exacerbation of COPD in frequent exacerbators. *International Journal of Chronic Obstructive Pulmonary Disease*, 341-349.



55. Gómez-Rosero, J. A., Cáceres-Galvis, C., Ascuntar, J., Atencia, C., Vallejo, C. E., & Jaimes, F. (2021). Biomarkers as a prognostic factor in COPD exacerbation: a cohort study. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 18(3), 325-332
56. Andelid, K., Bake, B., Rak, S., Lindén, A., Rosengren, A., & Ekberg-Jansson, A. (2007). Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. *Respiratory medicine*, 101(5), 888-895.
57. Houghton, A. M., Rzymkiewicz, D. M., Ji, H., Gregory, A. D., Egea, E. E., Metz, H. E., ... & Shapiro, S. D. (2010). Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. *Nature medicine*, 16(2), 219-223.
58. Furutate, R., Ishii, T., Motegi, T., Hattori, K., Kusunoki, Y., Gemma, A., & Kida, K. (2016). The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. *Internal Medicine*, 55(3), 223-229.
59. Lee, S. J., Lee, H. R., Lee, T. W., Ju, S., Lim, S., Go, S. I., ... & Lee, J. D. (2016). Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. *The Korean journal of internal medicine*, 31(5), 891
60. Taylan, M., Demir, M., Kaya, H., Selimoglu Sen, H., Abakay, O., Carkanat, A. İ., ... & Sezgi, C. (2017). Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. *The clinical respiratory journal*, 11(3), 311-317
61. Tanriverdi, H., Örnek, T., Erboy, F., Altinsoy, B., Uygur, F., Atalay, F., & Tor, M. M. (2015). Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. *Wiener Klinische Wochenschrift*, 127
62. Van de Geijn, G. J., Denker, S., Meuleman-van Waning, V., Koeleman, H. G. M., Birnie, E., Braunstahl, G. J., & Njo, T. L. (2016). Evaluation of new laboratory tests to discriminate bacterial from nonbacterial chronic obstructive pulmonary disease exacerbations. *International Journal of Laboratory Hematology*, 38(6), 616-628



miRad, S., RahimiRad, M., & Ghaffari, M. (2017). Association between neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of COPD

64. Xiong, W., Xu, M., Zhao, Y., Wu, X., Pudasaini, B., & Liu, J. M. (2017). Can we predict the prognosis of COPD with a routine blood test?. *International journal of chronic obstructive pulmonary disease*, 615-625.
65. Saltürk, C., Karakurt, Z., Adiguzel, N., Kargin, F., Sari, R., Celik, M. E., ... & Oztas, S. (2015). Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit?. *International journal of chronic obstructive pulmonary disease*, 1837-1846.
66. Vaguliene, N., Zemaitis, M., Lavinskiene, S., Miliauskas, S., & Sakalauskas, R. (2013). Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. *BMC immunology*, 14(1), 1-11.
67. Yasar, Z., Buyuksirin, M., Ucsular, F. D., Kargi, A., Erdem, F., Talay, F., & Kurt, O. K. (2015). Is an elevated neutrophil-to-lymphocyte ratio a predictor of metabolic syndrome in patients with chronic obstructive pulmonary disease. *Eur Rev Med Pharmacol Sci*, 19(6), 956-62.
68. Arisoy, A., Memiç, K., Diken, O. E., Karavelioglu, Y., Demirelli, S., Topçu, S., & Degirmenci, H. (2015). Evaluation of atrial conduction features in stable chronic obstructive pulmonary disease patients and its relationship with neutrophil to lymphocyte ratio.
69. Lee, H., Um, S. J., Kim, Y. S., Kim, D. K., Jang, A. S., Choi, H. S., ... & Jung, K. S. (2016). Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease. *PloS one*, 11(6), e0156511.
70. Ernst, P., Saad, N., & Suissa, S. (2015). Inhaled corticosteroids in COPD: the clinical evidence. *European Respiratory Journal*, 45(2), 525-537.
71. Sørensen, A. K., Holmgaard, D. B., Mygind, L. H., & Johansen, J. (2015). Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality—a cohort study. *Journal of Inflammation*, 12(1), 1-12.
72. Gil, H. I., Zo, S., Jones, P. W., Kim, B. G., Kang, N., Choi, Y., ... & Shin, S. H. (2021). Clinical characteristics of COPD patients according to COPD assessment test (CAT) score level: cross-sectional study. *International Journal of Chronic Obstructive Pulmonary Disease*, 1509-1517.



lemanuel, G. G., Mingude, A. B., & Geta, T. G. (2019). Prevalence of chronic obstructive pulmonary disease (COPD) and its associated factors

- among adults in Abeshge District, Ethiopia: a cross sectional study. *BMC Pulmonary Medicine*, 19(1), 1-9.
74. Jain, N. K., Thakkar, M. S., Jain, N., Rohan, K. A., & Sharma, M. (2011). Chronic obstructive pulmonary disease: Does gender really matter?. *Lung India: official organ of Indian Chest Society*, 28(4), 258.
 75. De Matteis, S., Jarvis, D., Darnton, A., Hutchings, S., Sadhra, S., Fishwick, D., ... & Cullinan, P. (2019). The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. *European Respiratory Journal*, 54(1).
 76. Karamina, A., Akyas, F., & Iryanto, M. P. (2018, October). Relationship between job and smoking habits based on the CART method. In *AIP Conference Proceedings* (Vol. 2021, No. 1). AIP Publishing.
 77. Divo, M., Cote, C., de Torres, J. P., Casanova, C., Marin, J. M., Pinto-Plata, V., ... & BODE Collaborative Group. (2012). Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*, 186(2), 155-161.
 78. Hillas, G., Perlikos, F., Tsiligianni, I., & Tzanakis, N. (2015). Managing comorbidities in COPD. *International journal of chronic obstructive pulmonary disease*, 95-109.
 79. Sharma, K., Garg, K., Joshi, J. L., Chopra, V., & Kundal, R. K. (2023). Neutrophil-Lymphocyte Ratio as a Predictor of COPD Exacerbations: A Cross-sectional Study. *Journal of Clinical & Diagnostic Research*, 17(1).
 80. Van Avondt, K., Strecker, J. K., Tulotta, C., Minnerup, J., Schulz, C., & Soehnlein, O. (2023). Neutrophils in aging and aging-related pathologies. *Immunological Reviews*, 314(1), 357-375.
 81. Guo, J., Zhang, H., Li, Y., Hao, M., Shi, G., Wang, J., ... & Wang, X. (2021). Neutrophil-lymphocyte ratio as a predictor of slow gait speed in older adults: the Rugao longitudinal aging study. *Experimental Gerontology*, 152, 111439.
 82. Chis AF, Pop CM. Correlations between neutrophil to lymphocyte ratio, blood eosinophils and clinical characteristics in chronic obstructive pulmonary disease. *Med Pharm reports*. 2020 Apr;93(2):169–74



ni, M., Chauhan, V., Singh, K., Rastogi, S., Agarwal, C., & Gera, K. (2021). effect and correlation of smoking with platelet indices, neutrophil hocyte ratio and platelet lymphocyte ratio. *Hematology, Transfusion and Therapy*, 43, 424-429.

84. Hlapčić, I., Dugac, A. V., Popović-Grič, S., Markelić, I., Rako, I., Rogić, D., & Rumora, L. (2022). Influence of disease severity, smoking status and therapy regimes on leukocyte subsets and their ratios in stable chronic obstructive pulmonary disease. *Archives of Medical Science: AMS*, 18(3), 672.
85. Adane, T., Melku, M., Worku, Y. B., Fasil, A., Aynalem, M., Kelem, A., & Getawa, S. (2023). The Association between Neutrophil-to-Lymphocyte Ratio and Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Journal of Diabetes Research*, 2023.
86. Miller, J., Edwards, L. D., Agustí, A., Bakke, P., Calverley, P. M., Celli, B., ... & Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. (2013). Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respiratory medicine*, 107(9), 1376-1384.
87. Ozyurek, B. A., Ozdemirel, T. S., Ozden, S. B., Erdogan, Y., Kaplan, B., & Kaplan, T. (2017). Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. *Asian Pacific journal of cancer prevention: APJCP*, 18(5), 1417.
88. Morgan, A. D., Zakeri, R., & Quint, J. K. (2018). Defining the relationship between COPD and CVD: what are the implications for clinical practice?. *Therapeutic advances in respiratory disease*, 12, 1753465817750524.
89. Miller, J., Edwards, L. D., Agustí, A., Bakke, P., Calverley, P. M., Celli, B., ... & Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. (2013). Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respiratory medicine*, 107(9), 1376-1384.
90. Thomsen, M., Ingebrigtsen, T. S., Marott, J. L., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2013). Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. *Jama*, 309(22), 2353-2361.





REKOMENDASI PERSETUJUAN ETIK

Nomor : 504/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 24 Juli 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23060441	No Sponsor	
Peneliti Utama	dr. Rosdiana	Sponsor	
Judul Peneliti	Hubungan Rasio Neutrofil Limfosit terhadap Keparahan Penyakit Paru Obstruktif Kronik		
No Versi Protokol	1	Tanggal Versi	27 Juni 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 24 Juli 2023 sampai 24 Juli 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan Laporan akhir setelah Penelitian berakhir
- Menyerahkan Laporan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Menyerahkan Laporan pelanggaran yang ditentukan





KEMENTERIAN KESEHATAN REPUBLIK INDONESIA

DIREKTORAT JENDERAL PELAYANAN KESEHATAN

RUMAH SAKIT UMUM PUSAT DR. WAHIDIN SUDIROHUSODO

Jalan Perintis Kemerdekaan Km. 11 Tamalanrea, Makassar, Kode Pos 90245

Telp. (0411) 584675 – 581818 (*Hunting*), Fax. (0411) 587676

Laman : www.rsupwahidin.com Surat Elektronik : tu@rsupwahidin.com



Nomor : DP.04.03/D.XIX.2/15116/2023
Hal : Izin Penelitian

13 Agustus 2023

Yth. Ketua Program Studi Pulmonologi dan Kedokteran Respirasi
Fakultas Kedokteran Universitas Hasanuddin

Sehubungan dengan surat saudara nomor **17694/UN4.6.8/PT.01.04/2023**, tertanggal **27 Juli 2023**, hal **Permohonan Izin Penelitian**, dapat kami fasilitasi dan memberikan izin pelaksanaan penelitian kepada:

Nama : **dr. Rosdiana**
NIM : **C185192003**
Prog. Pend. : **PPDS Ilmu Pulmonologi dan Kedokteran Respirasi**
No. HP : **082394993693**
Judul : **Hubungan Rasio Neutrofil Limfosit terhadap Keparahan Penyakit Paru Obstruktif Kronik di RSUP Dr. Wahidin Sudirohusodo Makassar**
Jangka Waktu : **Tiga Bulan Setelah Surat ini di Keluarkan**
Lokasi : **Inst. Sistem Informasi Rumah Sakit**

dengan ketentuan sebagai berikut :

1. Sesuai dengan peraturan dan ketentuan penelitian yang berlaku di lingkup RSUP Dr Wahidin Sudirohusodo
2. Sebelum meneliti, peneliti wajib melapor kepada Pengawas Penelitian di masing-masing unit yang menjadi lokasi penelitian
3. Pelaksanaan penelitian tidak mengganggu proses pelayanan serta mendukung upaya peningkatan mutu pelayanan dan keselamatan pasien
4. Pemeriksaan penunjang, BHP dan lain-lain yang digunakan dalam penelitian, menjadi tanggung jawab peneliti, tidak dibebankan kepada pasien ataupun RS
5. Peneliti melaporkan proses penelitian secara periodik serta hasil penelitian di akhir waktu penelitian
6. Mencantumkan nama RSUP Dr Wahidin Sudirohusodo sebagai afiliasi institusi dalam naskah dan publikasi penelitian
7. Surat Keterangan Selesai Penelitian menjadi salah satu syarat untuk mengikuti Seminar Hasil Penelitian
8. Bukti Penyerahan Skripsi/Thesis/Disertasi ke RSUP Dr Wahidin Sudirohusodo menjadi syarat penyelesaian studi

Mohon dapat dipastikan agar ketentuan tersebut dipenuhi peneliti sebelum menyelesaikan studi di institusi saudara. Atas perhatian dan Kerjasama yang baik, diucapkan terima kasih.

a.n. Direktur Utama
Plt. Direktur Sumber Daya Manusia,
Pendidikan dan Penelitian,



Ridhayani B, SKM, M.Kes
NIP197110271997032001



stem Informasi Rumah Sakit

Optimized using
trial version
www.balesio.com